Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity (2016 - 2025)

Historic Common Equity for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $639.1 million.

  • Viking Therapeutics' Common Equity fell 2740.23% to $639.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $639.1 million, marking a year-over-year decrease of 2740.23%. This contributed to the annual value of $639.1 million for FY2025, which is 2740.23% down from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Common Equity is $639.1 million, which was down 2740.23% from $713.0 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Common Equity ranged from a high of $933.9 million in Q1 2024 and a low of $134.1 million during Q1 2023
  • In the last 5 years, Viking Therapeutics' Common Equity had a median value of $358.3 million in 2023 and averaged $470.0 million.
  • As far as peak fluctuations go, Viking Therapeutics' Common Equity crashed by 2901.45% in 2022, and later soared by 59659.64% in 2024.
  • Over the past 5 years, Viking Therapeutics' Common Equity (Quarter) stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then surged by 139.76% to $348.4 million in 2023, then soared by 152.65% to $880.3 million in 2024, then decreased by 27.4% to $639.1 million in 2025.
  • Its last three reported values are $639.1 million in Q4 2025, $713.0 million for Q3 2025, and $795.5 million during Q2 2025.